Penumbra stock surges on approval hopes

Published 09/05/2025, 16:02
© Reuters.

Investing.com -- Shares of Penumbra (NYSE:PEN) rose by 5% following comments from Piper Sandler analyst Matt O’Brien, who indicated that the medical device company’s Thunderbolt product might receive regulatory approval sooner than anticipated. This potential development has sparked investor optimism, as the approval timeline seems to be moving ahead of initial expectations.

O’Brien, based on industry channel checks, suggested that Penumbra’s sales force is gearing up for product demonstrations of the Thunderbolt device, hinting at a possible approval within the next few weeks. This would be a significant advancement from the previously expected data release set for July and the general consensus of a third-quarter approval. "… the device could get approval in the next few weeks, which would be ahead of the data they expect to release on the product in July," O’Brien stated.

The early approval of Thunderbolt is not currently factored into the Street’s projections for the company’s financial performance this year. If the device is approved ahead of schedule, it could provide a substantial boost to Penumbra’s revenue, as the market has not yet accounted for Thunderbolt sales in this fiscal period. The anticipation of this event has contributed to the stock’s upward movement, as investors anticipate a positive impact on the company’s top-line growth.

O’Brien remains bullish on Penumbra, reiterating an overweight (OW) rating on the stock. He believes that once the Thunderbolt device is available, there will be significant interest and trialing from the medical community. The analyst’s outlook reflects confidence in the company’s potential to outperform market expectations and deliver value to shareholders.

Investors are now closely monitoring Penumbra’s progress with the Thunderbolt device, as an early approval could signify a notable competitive edge for the company within the medical device sector. The stock’s movement today reflects the market’s reaction to these developments and the high stakes involved in the timely approval of new medical technologies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.